Importance of the field: In patients undergoing vascular surgery there is a high incidence of adverse cardiac events, due to sudden coronary plaque rupture. The non-lipid lowering or pleiotropic effects of statins can help reduce adverse cardiovascular events associated with vascular surgery. Areas covered in this review: The evidence for perioperative use of fluvastatin, as well as other statins, in high-risk surgery patients is summarized in this review. Data on pharmacokinetics and metabolism is presented, together with considerations on possible drug interactions in the perioperative period. What the reader will gain: The reader will gain a comprehensive understanding of the existing safety and efficacy data for fluvastatin and other statins in the perioperative period. The practical considerations of perioperative fluvastatin therapy will be presented, including potential side-effects and management of the early non-oral phase immediately post surgery. Finally, advice on when to initiate therapy and safety recommendations are offered. Take home message: In patients scheduled for high-risk vascular surgery, fluvastatin improves postoperative outcome, reducing the incidence of myocardial damage by ∼ 50% in the first 30 days following vascular surgery. In comparison with placebo, fluvastatin was not associated with a rise in liver enzymes or creatine kinase levels. To bridge the non-oral phase, an extended-release formula is recommended.

Cardiovascular risk, Fluvastatin, Myocardial Infarction, Perioperative therapy, Statins, Vascular surgery,
Expert Opinion on Drug Safety
Erasmus MC: University Medical Center Rotterdam

Voûte, M.T, Winkel, T.A, & Poldermans, D. (2010). Safety of fluvastatin in patients undergoing high-risk non-cardiac surgery. Expert Opinion on Drug Safety (Vol. 9, pp. 793–800). doi:10.1517/14740338.2010.499120